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ABSTRACT 
OBJECTIVE: Compare the risk of reproductive and infant outcomes between male childhood 
cancer survivors and a population-based comparison group. 
DESIGN: Retrospective cohort study.  
SETTING: 4 U.S. regions. 
PARTICIPANTS: Cancer registries identified males <20 years old diagnosed with cancer 1973-
2000. Linked birth certificates identified first subsequent live offspring (n=470). Comparison 
subjects were identified from remaining birth certificates, frequency-matched on year and age at 
fatherhood, and race/ethnicity (n=4150).  
MAIN EXPOSURE: Cancer diagnosis prior to age 20. 
OUTCOME MEASURES: Pregnancy and infant outcomes identified from birth certificates. 
RESULTS: Compared with infants born to unaffected males, offspring of cancer survivors had a 
borderline risk of birth weight <2500 g (RR 1.43, 95% CI 0.99-2.05), with risk associated most 
strongly with younger age of cancer diagnosis and exposure to any chemotherapy (RR 1.96, 95% 
CI 1.22-3.17) or radiotherapy (RR 1.95, 95% CI 1.14-3.35). However, they were not at risk of 
being born prematurely, small for gestational age, having malformations or an altered 
male:female sex ratio. Overall, female partners of male survivors were not more likely to have 
maternal complications recorded on birth records versus the comparison group. However, 
preeclampsia was associated with some cancers, especially central nervous system tumors (RR 
3.36, 95% CI 1.63-6.90). 
CONCLUSIONS: Most pregnancies resulting in live births among partners of male childhood 
cancer survivors were not at significantly greater risk of complications versus comparison 
 Page 3 of 22 
PRECANS-male submitted  12/19/08 
subjects. The possibility of a paternal component affected by prior cancer history influencing 
predisposition towards some adverse perinatal outcomes merits further investigation. 
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INTRODUCTION 
 Chemotherapy, radiotherapy, and surgery for cancer treatment may impair future 
reproductive potential, and concerns about fertility and the health of any progeny are increased 
among survivors of childhood cancers compared with siblings(1;2). Most prior reports are based 
on institutional case series with self-reported reproductive outcomes. There have been fewer 
studies utilizing population-based data, and most were only able to examine a limited number of 
outcomes: fertility rate, sex ratio, and rates of malformations and cancer among progeny(3-8). In 
general, these studies suggest that although male survivors are less likely to father children 
versus comparison subjects or population norms, pregnancies they fathered have few other 
complications, and adverse outcomes among progeny are not increased.  
We identified a population-based sample of male childhood cancer survivors from 4 U.S. 
regions and linked their records to state birth certificate registries in order to describe the 
proportion that subsequently fathered live births. We then compared the occurrences of selected 
pregnancy conditions and infant outcomes between partners of male cancer survivors and those 
of a population-based comparison group identified from birth records. 
 
METHODS  
Subject identification and data linkage 
Human subject protection committee approval was received by the appropriate 
institutions and State Departments of Health prior to the conduct of this study. Methods used to 
identify subjects and to link data are described in detail in an accompanying paper(9). Briefly, 
incident cancer cases occurring among males <20 years old, newly diagnosed with cancer 
(malignant and in-situ) were identified from 4 population-based cancer registries participating in 
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the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program 
over the following time intervals: the Cancer Surveillance System of Western Washington in 
Seattle (1974-95); the Karmanos Cancer Institute of Wayne State University in Detroit, 
Michigan (1973-2000); the Utah Cancer Registry at the University of Utah (1973-98); and the 
SEER registry in Atlanta, Georgia (1975-2000). Aside from Utah, these registries are not 
statewide but only include the named metropolitan region plus surrounding counties (registry 
details may be found at: http://seer.cancer.gov/registries/index.html). The registries provided data 
on patients’ demographics, tumor characteristics, and initial course of treatment (any 
chemotherapy, any surgery, any radiotherapy, and non-overlapping combinations). Childhood 
cancer diagnoses were categorized using the International Classification of Childhood Cancer 
(ICCC)(10), with categories corresponding to neuroblastoma and related tumors, embryonal 
renal and hepatic tumors, and retinoblastoma collapsed into a single embryonal tumor category 
because of small numbers(11). The anatomical primary cancer site also was categorized as to 
whether it occurred within the pelvis. Cancer relapse information was unavailable. 
Birth certificate data from all 4 states were linked to each cancer patient’s registry record 
to identify the live born delivery occurring in closest temporal proximity following the subject’s 
cancer diagnosis date for these available years: Washington 1974-2001, Utah 1973-2001, 
Michigan 1975-2001, and Georgia 1980-2000. Routine linkage strategies varied by state, with 
available linkage variables including patient’s first and last names, sex, birth dates, birth place 
(Utah only), race/ethnicity (Georgia only), and social security number (Utah, Michigan, and 
Georgia). 483 potential subjects were identified from the 4 regions and were linked to the birth 
records in each state. Records of live born deliveries that occurred prior to a subject’s cancer 
diagnosis were not used in this study. 
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For comparison, men who fathered infants born during the same year were randomly 
selected from among the remaining birth records at a comparison:case subject ratio of 4:1 in 
Michigan, and 10:1 in the other 3 states. These also were frequency matched on the cancer 
survivor’s age at delivery (5-year intervals from <20 to ≥40 years) and race/ethnicity. On 
examination of the linked file it was determined that some potential cases were ineligible and 
subsequently excluded: 12 benign lesions and one basal cell skin tumor. In addition, 2 records 
associated with comparison subjects were of fetal deaths and excluded as the analysis focused on 
live births only. This resulted in 470 cancer survivors and 4150 comparison subjects used in the 
final analysis.  
 
Outcomes evaluated 
Outcomes occurring to female partners that could be evaluated using birth records 
included delivery type, maternal anemia, diabetes, and preeclampsia. Infant outcomes included 
birth weight (<2500, 2500-3999, ≥4000 g), gestational age (<37, 37-41, ≥42 weeks), small for 
gestational age (SGA; defined as <10% birth weight for gestational age and gender based on a 
representative national sample(12)), the presence of any malformation, 5-minute Apgar score <7 
(unavailable in Michigan), and infant death <12 months of age (unavailable in Georgia). Other 
information available for most records included the female partner’s prenatal smoking status, 
marital status, number of prior pregnancies and births, and when prenatal care was initiated. No 
information on assisted reproductive techniques was available.  
 
Statistical Analyses 
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 The number of cancer survivors in each region who linked with birth certificates and the 
total number of cases ascertained in each SEER region over the same time period (SEER*Stat 
database, version 6.1.4, 2005) were used to calculate the proportion of survivors in each region 
identified with subsequent live births. The distribution of selected parental characteristics, 
maternal and infant outcomes was described for cancer survivors and comparison subjects. 
Relative risks (RR) estimated using stratified Mantel-Haenszel methods were used, with results 
similar to those produced by logistic regression, log-binomial, or Poisson models(13). All RRs 
were adjusted for state, the frequency-matched variables, and maternal age and parity. Other 
variables considered for their possible role in the relationships of interest included: infant gender, 
maternal race/ethnicity, prenatal smoking, marital status, and duration of prenatal care. However, 
except where noted, adjustment by these variables did not meaningfully alter the RR estimates, 
and only those variables whose inclusion resulted in such change were retained in the analyses. 
Sensitivity analyses where births occurring within 9 months of diagnosis, multiple gestation 
births, and multiparous partners were excluded showed similar results. Analyses were conducted 
using STATA (version 9, StataCorp, College Station, TX). 
 
RESULTS 
Characteristics of cancer cases and comparison subjects 
General diagnostic and treatment characteristics of male cancer survivors (Table 1) were 
similar across SEER regions, with several exceptions: a greater proportion of cases from Detroit 
had 11-30 years elapse between diagnosis and subsequent delivery (70% versus 34-39% in other 
regions); the prevalence of skin cancer ranged from 3% in Detroit to 12% in Utah; and selected 
cancer treatments varied (chemotherapy only ranged from 8% in Utah to 19% in Seattle; surgery 
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plus radiotherapy ranged from 5% in Detroit to 18% in Atlanta; and any surgery ranged from 
52% in Detroit to 70% in Utah). Overall, the proportion of childhood cancer patients identified 
from birth records as having fathered a live birth ranged from 4% in Detroit to 11% in Utah, with 
an overall mean time from cancer diagnosis to fatherhood of 10.2 ± SD 5.8 years. 
Compared with all childhood cancer cases ascertained by SEER in the 4 regions during 
the study period (per SEER*Stat), the subset of cases linked in this study was more likely to be 
diagnosed in an earlier era (pre-1990, 85% versus 60%) and at an older age (≥10 years, 86% 
versus 50%), and less likely to have those cancers associated with younger age at diagnosis 
(leukemia, 11% versus 25%; embryonal tumors, 5% versus 13%).  
Paternal race/ethnicity, age, and year of delivery, being frequency matched by design, 
were similar for cancer survivors and comparison subjects (Table 2). The median age of 
survivors and comparison subjects at delivery was 25 (range 16-40) and 24 (range 16-47) years, 
respectively. The two groups also were similar with respect to female partner’s age, 
race/ethnicity, prenatal smoking status, and the proportion with multiple gestation births (3% 
versus 2%, data not shown). However, greater proportions of survivors had female partners who 
were recorded as being unmarried, primigravida, and nulliparous.  
 
Overall pregnancy and infant outcomes 
Overall, female partners of cancer survivors had similar risks of selected pregnancy-
related conditions compared with partners of comparison subjects (Table 3). Among infant 
outcomes, the male:female offspring sex ratio did not differ significantly between survivors and 
comparison subjects (1.09 versus 1.04, respectively; RR for having male offspring 1.03, 95% CI 
0.93-1.14). Cancer survivors had a borderline risk of fathering infants with low birth weight 
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<2500 g (RR 1.43, 95% CI 0.99-2.05), but no risk of having infants weighing <1500 g (RR 1.16, 
95% CI 0.46-2.93, data not shown). These risk estimates were not affected by adjustment for 
gestational age and maternal factors such as prenatal smoking, preeclampsia, or diabetes. 
Offspring of survivors did not have an increased risk of being born <37 weeks gestation. 
Furthermore, although the proportion of preterm infants <2500 g was slightly greater among 
cases (55%) than comparison infants (48%), offspring of survivors were not at increased risk of 
meeting SGA criteria. The RRs for infant malformations and 5-minute Apgar score <7 also were 
not increased and there were no infant deaths among progeny of cancer survivors. 
 
Outcomes stratified by diagnostic and treatment characteristics 
 When maternal and infant outcomes were stratified by cancer subtype and pelvic cancer 
location, no consistent associations were seen for C-section, maternal diabetes or anemia, 
preterm delivery, and infant malformations. However, partners of males with childhood central 
nervous system tumors (RR 3.36, 95% CI 1.63-6.90) and leukemia (RR 2.41, 95% CI 1.11-5.22) 
had an increased risk of preeclampsia (Table 4), even after additional adjustment for maternal 
diabetes. However, no other consistent associations for preeclampsia were observed among other 
subgroups.  
Significant increased risks of fathering a low birth weight infant were associated with 
embryonal tumors (RR 3.93, 95% CI 1.68-9.20; Table 4). No secular trends were observed 
except for an increased risk of low birth weight associated with earlier treatment era (pre-1980) 
that diminished over subsequent decades. Young age at diagnosis (<5 years) and greatest elapsed 
time since diagnosis (>10 years) also were associated with birth weight <2500 g. Treatments 
involving any chemotherapy (RR 1.96, 95% CI 1.22-3.17) or any radiotherapy (RR 1.95, 95% CI 
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1.14-3.35) were associated with a greater risk of low birth weight, but not exposure to surgery 
alone. Patients who had primary tumors in the abdomen treated with any radiotherapy also were 
at risk (RR 3.38, 95% CI 1.49-7.68; data not shown). Risk estimates for combination therapies 
were more variable, but in general, those containing chemotherapy tended to be greater than 
those without chemotherapy, with the greatest risk associated with exposure to all three 
modalities (RR 3.47, 95% CI 1.36-8.85). Borderline associations for SGA infant also were seen 
following treatment with any radiotherapy (RR 1.58, 95% CI 1.03-2.42) and combination 
chemotherapy with radiotherapy (RR 2.29, 95% CI 1.13-4.63), but not with other subgroups. 
Fathers with pelvic primary tumors had an offspring male:female sex ratio of 1.18, but 
the likelihood of having male offspring was not increased significantly (RR 1.02, 95% CI 0.84-
1.26; data not shown). Infant male:female sex ratios was greatest for those ages 10 to 14 years at 
diagnosis (1.18), but similar for all other diagnosis age categories (range 1.06-1.07; data not 
shown). Infant male:female sex ratios following any radiotherapy, any chemotherapy, and 
surgery only were 1.23, 1.16, and 0.93, respectively, but none of these were significantly 
different from those of comparison subjects, even after multivariable adjustment or restriction to 
those with pelvic tumors.  
 
DISCUSSION 
 Few studies(14;15) have examined associations between paternal cancer history and 
subsequent pregnancy complications among female partners and outcomes among offspring 
outside of malformations or cancer. In this study of a relatively contemporary cohort of male 
childhood cancer survivors, partners and progeny of cancer survivors were not at increased risk 
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of most complications examined. However, we did observe an increased risk of low birth weight 
and preeclampsia associated with some treatment characteristics.  
Based on self-reported outcomes of more than 1500 live births, the North American 
Childhood Cancer Survivor Study reported a 3-fold increased risk of low birth weight progeny 
among male childhood survivors treated with nonalkylating chemotherapy compared with 
siblings(14). Risk estimates associated with pelvic radiation and alkylating chemotherapy (RR 
1.5-1.6) were not significantly increased, but were similar in magnitude to ours. Gestational age 
was not examined in this study. A registry-based study examining several hundred Norwegian 
male cancer survivors diagnosed between 15 to 35 years of age did not report an increased risk 
of low birth weight progeny(15). However, given that our estimates were greatest for males 
diagnosed <15 years of age, differences in the study populations and their exposures may 
account for this discrepancy. Nevertheless, in neither study was there a consistent risk of progeny 
being delivered preterm.  
Both maternal and paternal contributions to birth weight have been reported in the 
general population. Parents who were themselves low birth weight infants tend to give birth to 
low birth weight infants independent of environmental factors(16;17). Although we did not know 
parental birth weights, there is no reason to suspect that male cancer survivors or their partners 
would more likely have been low birth weight infants themselves. Aside from hepatoblastoma 
(there were no cases in this study), low birth weight has not been associated consistently with an 
increased risk of childhood cancers(18). Additional maternal demographic and environmental 
factors associated with low birth weight include nulliparity, very young or older maternal age, 
prior low birth weight infant, lower socioeconomic status, and substance use including tobacco 
exposure(19). We attempted to adjust for many of these factors, but it is possible residual 
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confounding exists as childhood cancer survivors, particularly central nervous system tumor 
patients, are more likely to be unmarried(20) and unemployed(21), though less likely to 
smoke(22). Nevertheless, it is interesting that risk was increased after exposure to chemotherapy 
and radiotherapy, but not to surgery alone. Compared with maternal associations, any paternal 
influence on infant birth weight is more likely to be genetic rather than environmental(17;23). 
There is evidence that the imprinting of fetal genes can affect fetal growth and adult health(24), 
although there is no evidence that prior cancer therapy in the father affects imprinting of germ 
line cells, particularly as epigenetic therapies would not have been widely used during the study 
period.  
It is unclear why preeclampsia was associated with central nervous system tumors, and to 
a lesser degree, leukemias. Although we examined maternal factors that can be associated with 
preeclampsia in our analysis such as age, nulliparity, and diabetes, it is possible these findings 
could still reflect residual confounding, or be due to chance. Prior studies generally have not 
examined preeclampsia among partners of male cancer survivors. One study of male 
hematopoietic cell transplant survivors found that 6% of partners (n=4) experienced 
preeclampsia(25), similar to the prevalence in our study but also within estimated population 
rates(26). A paternal contribution to preeclampsia has been reported in the general population, 
suggesting that paternally-derived fetal genes are involved in pathogenesis(27;28). The 
mechanism by which paternal genes affect preeclampsia is unclear, although a role for paternally 
imprinted alleles also has been hypothesized(27). However, as with low birth weight, it is 
unclear if cancer therapy affects germ line imprinting. Although loss of imprinting is an 
increasingly recognized phenomena among pediatric and adult cancers, these changes typically 
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are restricted to tumor cells with the exception of certain rare cancer predisposition 
syndromes(29).  
 Previous studies have investigated possible mutagenic effects of cancer therapy on germ 
cells as manifested by an altered male:female progeny sex ratio, malformations, and miscarriages 
or stillbirths. In our study, the male:female progeny sex ratio was slightly greater among 
survivors (1.09) compared with comparison subjects (1.04), and greatest among those with 
pelvic tumors and those exposed to any chemotherapy or radiotherapy (range 1.16-1.23). In 
comparison, over the past 50 years the U.S. ratio has been around 1.05(30). Although our 
estimates did not reach statistical significance, this pattern supports the hypothesis that 
mutagenic therapies could result in an increased male:female progeny ratio among treated fathers 
due to dominant lethal X-chromosome mutations. However, male:female sex ratios have not 
been increased in other studies of male childhood cancer survivors(6;8;31) and even significantly 
decreased in one(14).  
Most studies, including ours, have not reported increased risks of malformations 
(reviewed in Ref(32)), although our use of birth registry data may under-ascertain more subtle 
defects not diagnosed at birth. One birth registry study did report a 50% increased risk of 
malformations among progeny of adolescent and young adult male cancer survivors compared 
with the general population(15). An increased risk of miscarriage or stillbirths among partners of 
male cancer survivors(14) also suggests the possibility that mutagenic exposures may affect 
viability of future offspring.  
 Our study has several limitations. Although SEER audits have shown that case 
ascertainment exceeds 95% and that tumor characteristics(33) and broad treatment categories 
(e.g. chemotherapy, radiotherapy, and surgery) are accurately recorded(34), our data were 
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limited to initial cancer treatment. Information about treatment for relapse was not available and 
therefore our estimates for treatment categories contain some misclassification. The effects of 
this are difficult to predict as chemotherapy, radiotherapy, and surgery are all used for salvage 
treatments, but patients likely received more multi-modal therapy than shown.  
Although >99% of births in the US are captured on birth records(35), birth records have 
some limitations. Generally, paternal characteristics are not as thoroughly recorded as maternal 
characteristics, particularly if parents are unmarried(35). As male cancer survivors were less 
likely to be currently married than comparison subjects, this may in part explain why the 
percentage of cancer survivors identified as fathers (6.7%) was lower than in other studies, 
although birth registries do attempt to record paternal information even if the couple is 
unmarried. Migration to other states would also decrease our cancer-birth registry linkages. 
However, at least for recent years, U.S. Census surveys report <3% of people who move, move 
out-of-state, and concern regarding health is rarely cited as the primary reason for moving(36). 
Furthermore, migration would have affected our outcomes only if cases who moved out-of-state 
differed from those who remained, information we did not have access to. Finally, as the median 
age of survivors in this cohort was only 25 years, many survivors also are just entering 
reproductive age.  
Nevertheless, for successful linkages, birth record characteristics such as gravidity/parity, 
delivery method, infant gender, birth weight, and gestational age are recorded accurately with 
sensitivity/specificity typically >95% when compared with medical records(37). However, 
although the specificity of maternal comorbidities such as diabetes, preeclampsia, anemia, and 
tobacco exposure is typically high, sensitivity can be much more variable(37;38). Overall, there 
is no reason to suspect that partners of male cancer survivors would have birth record data 
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recorded differently than others; birth records should not be susceptible to response or recall 
biases. 
Misattributed paternity may also be present within our population. Although one may 
hypothesize that use of donor sperm may be more prevalent among cancer survivors, there is 
little information about its prevalence and we did not have any data on use of assisted 
reproductive techniques. Furthermore, the direction of any bias arising from misattributed 
paternity is difficult to predict. Among the general population, non-paternity rates have varied 
greatly across populations and have been associated with different demographic factors in 
various studies(39). 
Lastly, differences may exist between this cohort and the overall population of male 
childhood cancer cases. Despite follow-up of up to 28 years, our study, like many other studies 
of childhood illnesses that attempt to examine outcomes in adulthood, our subjects include more 
individuals who were diagnosed in earlier time periods and who were older at diagnosis. Cancers 
with increased reproductive morbidity and mortality also would be less represented in any 
survivor cohort. Nevertheless, for male survivors identified as fathers in state birth records, the 
vast majority of associated pregnancies resulting in live births were not at significantly greater 
risk of complications versus comparison subjects. However, our finding of increased low birth 
weight and preeclampsia associated with some diagnostic groups raise the possibility that prior 
cancer therapy may affect male germ cells with effects on female partners and progeny of male 
survivors.  
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Table 1. Diagnostic characteristics of male childhood cancer survivors with subsequent live 
offspring identified. 
Characteristic N (%) 
(n=470) 
Cancer registry, U.S. State  
   Atlanta, Georgia 91 (19.4) 
   Detroit, Michigan 103  (21.9)
   Seattle, Washington 122 (26.0) 
   Utah 154 (32.8) 
Year of diagnosis  
   1973-1979   170 (36.2) 
   1980-1989 229 (48.7) 
   1990-2000 71 (15.1) 
Age at diagnosis, years  
   <5 35 (7.5) 
   5-9 29 (6.2) 
   10-14 72 (15.3) 
   15-19 334 (71.1) 
Elapsed years until delivery  
   <2 23 (4.9) 
   2-5 92 (19.6) 
   6-10 151 (32.1) 
   11-30 204 (43.4) 
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Table 1. Diagnostic characteristics of male childhood cancer survivors with subsequent live 
offspring identified (cont). 
Cancer type1   
   Leukemia 51 (10.9) 
   Lymphoma 118 (25.1)
   Central nervous system 47 (10.0) 
   Embryonal2  25 (5.3) 
   Malignant bone 33 (7.0) 
   Soft tissue sarcoma 42 (8.9) 
   Germ cell/gonadal 61 (13.0) 
   Thyroid carcinoma 22 (4.7) 
   Non-basal/squamous cell skin 36 (7.7) 
   Other carcinoma 27 (5.7) 
   Other tumors 8 (1.7) 
Pelvic primary cancer site 85 (18.1) 
 
1 Based on the International Classification of Childhood Cancers (Ref 10). 
2 Consists of neuroblastoma and related tumors (n=10), embryonal renal (n=13) and hepatic 
(n=0) tumors, and retinoblastoma (n=2). 
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Table 1. Diagnostic characteristics of male childhood cancer survivors with subsequent live 
offspring identified (cont). 
Cancer treatment  
   Chemotherapy only 66 (14.0) 
   Surgery only 137 (29.2)
   Radiotherapy only 42 (8.9) 
   Chemotherapy+surgery 62 (13.2) 
   Chemotherapy+radiotherapy 50 (10.6) 
   Surgery+radiotherapy 55 (11.7) 
   Chemotherapy+surgery+radiotherapy 38 (8.1) 
   Other / unknown treatment 20 (4.3) 
Any chemotherapy 216 (46.0)
Any surgery 292 (62.1)
Any radiotherapy 185 (39.4)
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Table 2. Prenatal characteristics of male survivors and their partners at time of first 
subsequent offspring versus a comparison group.1 
 Cohort, N (%) 
Characteristic  Cancer survivors 
(n=470) 
Comparison group 
(n=4150) 
Father’s race/ethnicity   
   White 398 (84.5) 3502 (86.9) 
   African American 49 (10.8) 448 (11.1) 
   Asian 2 (0.4) 19 (0.5) 
   Native American 2 (0.4) 16 (0.4) 
   Other 4 (0.9) 45 (1.1) 
Mother’s race/ethnicity   
   White 399 (86.7) 3532 (86.6) 
   African American 50 (10.9) 413 (10.1) 
   Asian 4 (0.9) 43 (1.1) 
   Native American 3 (0.7) 34 (0.8) 
   Other 4 (0.9) 57 (1.4) 
 
1 Numbers may not add up to totals because of missing data. 
 Page 4 of 13 
PRECANS-male TABLES submitted  12/19/08 
Table 2. Prenatal characteristics of male survivors and their partners at time of first 
subsequent offspring versus a comparison group (cont). 
Father’s age at delivery, years   
   <20 36 (7.7) 363 (8.8) 
   20-24 187 (39.8) 1764 (42.5)
   25-29 169 (36.0) 1453 (35.0)
   30-34 61 (13.0) 461 (11.1) 
   35-39 16 (3.4) 94 (2.3) 
   ≥40 1 (0.2) 15 (0.4) 
Mother’s age at delivery, years   
   <20 97 (20.6) 783 (18.9) 
   20-24 176 (37.4) 1804 (43.5)
   25-29 129 (27.4) 1042 (25.1)
   30-34 59 (12.6) 412 (9.9) 
   35-39 8 (1.7) 97 (2.3) 
   ≥40 1 (0.2) 11 (0.27) 
Year of delivery   
   1973-1979 9 (1.9) 90 (2.2) 
   1980-1989 109 (23.2) 1046 (25.2)
   1990-1999 326 (69.4) 2801 (67.5)
   2000-2001 26 (5.5) 213 (5.1) 
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Table 2. Prenatal characteristics of male survivors and their partners at time of first 
subsequent offspring versus a comparison group (cont). 
Unmarried at time of delivery, mother2 92 (25.1) 739 (20.0) 
Prenatal smoker, mother3 64 (16.8) 480 (14.5) 
No. prior pregnancies, mother   
   0 293 (64.0) 1692 (41.6)
   1 96 (21.0) 1239 (30.5)
   ≥2 69 (15.1) 1135 (27.9)
No. prior births, mother   
   0 347 (75.8) 2004 (49.3)
   1 78 (17.0) 1291 (31.7)
   ≥2 33 (7.2) 772 (19.0) 
Month prenatal care began, mother   
   1st trimester 385 (84.3) 3294 (81.8)
   2nd trimester 51 (11.2) 601 (14.9) 
   3rd trimester or no care 21 (4.6) 133 (3.3) 
 
2 Data unavailable in Michigan. 
3 Not available for all years. 
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Table 3.  Perinatal outcomes associated with first subsequent offspring among male 
survivors versus a comparison group.1 
 Cohort, N (%) Relative Risk 
Outcome Cancer survivors
(n=470) 
Comparison group
(n=4150) 
 (95% CI)2  
Maternal conditions    
Any history of C-section 84 (18.5) 721 (18.0) 0.91 (0.73-1.14) 
Primary C-section3 65 (19.2) 374 (19.4) 0.91 (0.71-1.17) 
Diabetes4  
 
 
 
9 (2.2) 71 (2.0) 1.17 (0.55-2.51) 
Preeclampsia/eclampsia4 27 (6.5) 160 (4.4) 1.19 (0.76-1.88) 
Anemia4 3 (0.8) 79 (2.3) 0.46 (0.13-1.55) 
    
Infant outcomes    
Female gender 225 (47.9) 2033 (49.0) referent 
Male gender 245 (52.1) 2117 (51.0) 1.03 (0.93-1.14) 
Birth weight, grams    
   <2500 41 (8.7) 282 (6.8) 1.43 (0.99-2.05) 
   2500-3999 380 (80.9) 3465 (83.6) referent 
   ≥4000 49 (10.4) 397 (9.6) 1.08 (0.79-1.49) 
1 Numbers may not add up to totals because of missing data. 
2 Adjusted for state, infant birth year, paternal and maternal age, paternal race/ethnicity, and 
maternal parity.  
3 Among 345 male cancer survivors and 1979 comparison men whose partners did not have prior 
deliveries. 
4 Not available for all years. 
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Table 3.  Perinatal outcomes associated with first subsequent offspring among male 
survivors versus a comparison group (cont).  
Gestational age, weeks    
   <37 42 (9.1) 366 (9.0) 0.99 (0.70-1.41)
   37-41 381 (82.5) 3383 (83.5) referent 
   ≥42 39 (8.4) 305 (7.5) 1.18 (0.85-1.64)
Small for gestational age 43 (9.4) 414 (10.3) 0.91 (0.64-1.29)
Malformation4 9 (2.0) 86 (2.1) 0.83 (0.41-1.69)
5-minute Apgar <75 4 (1.1) 57 (1.6) 0.81 (0.29-2.29)
Infant death6 0 20 (0.6) - 
 
5 Not available for all years and unavailable in Michigan.  
6 Not available for all years and unavailable in Georgia. 
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Table 4. Selected perinatal outcomes associated with first subsequent offspring among male 
survivors versus a comparison group, stratified by diagnostic characteristics. 
 Relative Risk (95% CI)1  
Characteristic Maternal 
preeclampsia
Birth 
weight 
<2500 g 
Gestation 
<37 weeks 
Small for 
gestational 
age 
Cancer type     
  Leukemia 2.41 
(1.11-5.22) 
1.63 
(0.58-4.62)
0.44 
(0.10-2.03)
0.81 
(0.25-2.59) 
  Lymphoma 0.26 
(0.04-1.70) 
1.68 
(0.85-3.30)
0.59 
(0.22-1.54)
1.41 
(0.81-2.46) 
  Central nervous  
    system 
3.36 
(1.63-6.90) 
1.18 
(0.36-3.85)
1.31 
(0.55-3.12)
1.02 
(0.44-2.41) 
  Embryonal  0.46 
(0.04-4.84) 
3.93 
(1.68-9.20)
2.17 
(0.78-6.02)
1.51 
(0.46-4.99) 
  Bone 2.54 
(0.38-16.80) 
0.76 
(0.10-5.63)
0.42 
(0.07-2.56)
0.61 
(0.12-3.16) 
  Soft tissue  
    sarcoma  
1.19 
(0.22-6.39) 
0.69 
(0.19-2.44)
0.36 
(0.07-1.83)
1.15 
(0.38-3.52) 
  Germ cell/gonadal 0.71 
(0.14-3.67) 
1.72 
(0.75-3.96)
1.61 
(0.80-3.26)
0.48 
(0.15-1.53) 
 
1 Adjusted for state, infant birth year, paternal age and race/ethnicity, and maternal age and 
parity.  
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Table 4. Selected perinatal outcomes associated with first subsequent offspring among male 
survivors versus a comparison group, stratified by diagnostic characteristics (cont). 
  Thyroid 1.91 
(0.33-10.86)
- - 0.83 
(0.10-6.98) 
  Non-basal/squamous  
     cell skin 
1.08 
(0.25-4.74) 
1.33 
(0.45-3.95) 
2.39 
(1.19-4.80) 
0.56 
(0.14-2.23) 
  Other carcinoma - 1.03 
(0.18-5.93) 
- 0.57 
(0.11-3.07) 
  Other tumors - 1.61 
(0.04-65.73)
3.95 
(0.37-41.65)
- 
Pelvic primary cancer site 0.43 
(0.09-2.06) 
1.65 
(0.84-3.26) 
1.61 
(0.92-2.80) 
0.51 
(0.19-1.37) 
Diagnosis year     
  1973-1979 1.03 
(0.48-2.21) 
1.79 
(1.02-3.13) 
1.06 
(0.57-2.00) 
1.18 
(0.71-1.94) 
  1980-1989 1.60 
(0.91-2.83) 
1.42 
(0.87-2.30) 
1.10 
(0.69-1.75) 
0.86 
(0.52-1.44) 
  1990-2000 0.63 
(0.16-2.45) 
0.91 
(0.32-2.63) 
0.66 
(0.28-1.53) 
0.62 
(0.24-1.64) 
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Table 4. Selected perinatal outcomes associated with first subsequent offspring among male 
survivors versus a comparison group, stratified by diagnostic characteristics (cont). 
Age at diagnosis     
  <5 years 1.81 
(0.69-4.74)
2.78 
(1.21-6.38)
0.86 
(0.21-3.50)
1.59 
(0.62-4.10) 
  5-9 years 1.02 
(0.29-3.62)
2.27 
(0.73-7.09)
0.55 
(0.11-2.71)
2.13 
(0.97-4.71) 
  10-14 years 1.32 
(0.49-3.54)
2.06 
(0.88-4.80)
0.76 
(0.23-2.49)
1.04 
(0.46-2.32) 
  15-19 years 1.10 
(0.60-2.02)
1.13 
(0.71-1.79)
1.08 
(0.74-1.59)
0.72 
(0.45-1.14) 
Time since diagnosis     
  <2 years - 1.20 
(0.31-4.58)
0.89 
(0.22-3.62)
1.49 
(0.50-4.43) 
  2-5 years 1.48 
(0.56-3.93)
0.76 
(0.25-2.29)
0.74 
(0.31-1.74)
0.48 
(0.18-1.26) 
  6-10 years 0.85 
(0.35-2.10)
1.05 
(0.57-1.93)
0.84 
(0.47-1.51)
0.83 
(0.47-1.46) 
  >10 years 1.44 
(0.80-2.57)
2.28 
(1.36-3.82)
1.23 
(0.71-2.15)
1.27 
(0.76-2.13) 
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Table 4. Selected perinatal outcomes associated with first subsequent offspring among male 
survivors versus a comparison group, stratified by diagnostic characteristics (cont). 
Cancer treatment     
  Chemotherapy, 
    only 
2.41 
(1.03-5.63) 
1.55 
(0.58-4.11)
0.85 
(0.31-2.33)
0.38 
(0.07-2.01)
  Surgery, only 1.40 
(0.60-3.25) 
0.83 
(0.42-1.66)
1.27 
(0.74-2.18)
0.44 
(0.19-1.02)
  Radiotherapy, 
    only 
- 1.91 
(0.62-5.89)
0.83 
(0.22-3.11)
1.21 
(0.43-3.44)
  Chemotherapy 
    +surgery 
0.70 
(0.14-3.64) 
1.91 
(0.87-4.22)
1.46 
(0.76-2.81)
0.81 
(0.34-1.94)
  Chemotherapy 
    +radiotherapy 
1.19 
(0.31-4.64) 
1.78 
(0.68-4.62)
0.23 
(0.02-2.66)
2.29 
(1.13-4.63)
  Surgery 
    +radiotherapy 
2.08 
(0.95-4.57) 
1.35 
(0.42-4.30)
0.75 
(0.23-2.42)
1.09 
(0.46-2.59)
  Chemotherapy 
    +surgery 
    +radiotherapy 
0.32 
0.03-3.38) 
3.47 
(1.36-8.85)
1.36 
(0.46-4.04)
1.96 
(0.88-4.36)
  Other  
    / unknown 
0.93 
(0.14-6.18) 
1.47 
(0.22-9.79)
- 0.69 
(0.11-4.44)
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Table 4. Selected perinatal outcomes associated with first subsequent offspring among male 
survivors versus a comparison group, stratified by diagnostic characteristics (cont). 
Any chemotherapy 1.16 
(0.60-2.24) 
1.96 
(1.22-3.17)
1.03 
(0.63-1.70)
1.23 
(0.78-1.93) 
Any surgery 1.19 
(0.67-2.10) 
1.32 
(0.84-2.06)
1.21 
(0.82-1.78)
0.79 
(0.51-1.23) 
Any radiotherapy 0.97 
(0.49-1.95) 
1.95 
(1.14-3.35)
0.77 
(0.39-1.50)
1.58 
(1.03-2.42) 
 
